260 related articles for article (PubMed ID: 32241690)
1. Surface-enhanced Raman spectroscopy of preoperative serum samples predicts Gleason grade group upgrade in biopsy Gleason grade group 1 prostate cancer.
Qian H; Shao X; Zhu Y; Fan L; Zhang H; Dong B; Wang Y; Xu F; Zhen W; Kang X; Chen N; Liu S; Pan J; Xue W
Urol Oncol; 2020 Jun; 38(6):601.e1-601.e9. PubMed ID: 32241690
[TBL] [Abstract][Full Text] [Related]
2. Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S.
Pan J; Shao X; Zhu Y; Dong B; Wang Y; Kang X; Chen N; Chen Z; Liu S; Xue W
Int J Nanomedicine; 2019; 14():431-440. PubMed ID: 30666105
[TBL] [Abstract][Full Text] [Related]
3. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
4. Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.
Qian H; Wang Y; Ma Z; Qian L; Shao X; Jin D; Cao M; Liu S; Chen H; Pan J; Xue W
Int J Nanomedicine; 2022; 17():1635-1646. PubMed ID: 35411143
[TBL] [Abstract][Full Text] [Related]
5. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.
Terracciano D; Bruzzese D; Ferro M; Mazzarella C; Di Lorenzo G; Altieri V; Mariano A; Macchia V; Di Carlo A
Prostate; 2012 Jan; 72(1):100-7. PubMed ID: 21520165
[TBL] [Abstract][Full Text] [Related]
6. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.
Audenet F; Rozet F; Resche-Rigon M; Bernard R; Ingels A; Prapotnich D; Sanchez-Salas R; Galiano M; Barret E; Cathelineau X
Clin Genitourin Cancer; 2017 Dec; 15(6):e907-e913. PubMed ID: 28522288
[TBL] [Abstract][Full Text] [Related]
7. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study.
Shao X; Pan J; Wang Y; Zhu Y; Xu F; Shangguan X; Dong B; Sha J; Chen N; Chen Z; Wang T; Liu S; Xue W
Nanomedicine; 2017 Apr; 13(3):1051-1059. PubMed ID: 27979746
[TBL] [Abstract][Full Text] [Related]
10. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
[TBL] [Abstract][Full Text] [Related]
11. Machine learning prediction of Gleason grade group upgrade between in-bore biopsy and radical prostatectomy pathology.
Ozbozduman K; Loc I; Durmaz S; Atasoy D; Kilic M; Yildirim H; Esen T; Vural M; Unlu MB
Sci Rep; 2024 Mar; 14(1):5849. PubMed ID: 38462645
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer.
Hsieh TF; Chang CH; Chen WC; Chou CL; Chen CC; Wu HC
J Chin Med Assoc; 2005 Apr; 68(4):167-71. PubMed ID: 15850066
[TBL] [Abstract][Full Text] [Related]
13. Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer.
Stefancu A; Moisoiu V; Couti R; Andras I; Rahota R; Crisan D; Pavel IE; Socaciu C; Leopold N; Crisan N
Nanomedicine (Lond); 2018 Oct; 13(19):2455-2467. PubMed ID: 30284481
[TBL] [Abstract][Full Text] [Related]
14. Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL.
Chen N; Rong M; Shao X; Zhang H; Liu S; Dong B; Xue W; Wang T; Li T; Pan J
Int J Nanomedicine; 2017; 12():5399-5407. PubMed ID: 28794631
[TBL] [Abstract][Full Text] [Related]
15. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
16. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
[TBL] [Abstract][Full Text] [Related]
17. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
18. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
[TBL] [Abstract][Full Text] [Related]
19. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
20. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
